Serafini, Anna
Gerard, Elizabeth
Genton, Pierre
Crespel, Arielle
Gelisse, Philippe
Article History
First Online: 11 February 2019
Compliance with Ethical Standards
:
: No sources of funding were used to prepare this manuscript.
: Dr. Serafini has no conflicts of interest related to this article. Pr. Gerard has received speaker honoraria from UCB-China. She served as site principal investigator (PI) for industry-sponsored research (SAGE pharmaceuticals, Sunovion). She also serves as site PI for the MONEAD trial (U01NS038455). Dr. Genton has received speaker honoraria from Sanofi-Aventis, UCB, and Eisai. Dr. Crespel has received support from pharmaceutical companies for teaching programs (Sanofi-Aventis, UCB). Dr. Crespel served as a board member for Eisai-France. Dr. Gelisse has received support from pharmaceutical companies for teaching programs (Sanofi-Aventis, UCB, Psicofarma). He received a research grant from the French League Against Epilepsy and the Janssen-Cilag company. He was a paid consultant for Eisai-France in 2011.